FEM
ABMD

Fulcrum Equity Management’s Abiomed Inc ABMD Stock Holding History

Fulcrum Equity Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-25
Closed -$4K – 244
2019
Q3 		$4K Buy
+25
New +$5.4K ﹤0.01% 178

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fulcrum Equity Management's ABMD Position: Q4 2019 in Review

Fulcrum Equity Management sold out of Abiomed Inc (ABMD) in Q4 2019, closing a stake of 25 shares — an estimated $4K sold.

Fulcrum Equity Management first reported a position in ABMD in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 465 funds tracked by Wall St. Rank hold ABMD as of Q4 2019.

  • Fulcrum Equity Management reported no remaining Abiomed Inc position as of Q4 2019 after selling out during the quarter.
  • Fulcrum Equity Management sold 25 Abiomed Inc shares in Q4 2019, an estimated $4K.
  • Fulcrum Equity Management first reported a position in Abiomed Inc in Q3 2019 and held it in 1 quarter.
  • Fulcrum Equity Management's Abiomed Inc position peaked at $4K in Q3 2019.
  • 465 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2019.

Based on Fulcrum Equity Management's 13F filing for Q4 2019, filed 12 Feb 2020.